Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report) and keeping the price target at $45.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Rami Katkhuda’s rating is based on the promising clinical potential of Dianthus Therapeutics’ DNTH103, particularly in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The recent data presented by Sanofi on riliprubart, an active C1s inhibitor, demonstrated significant efficacy in patients who were either refractory to or naïve to standard of care treatments. This positions DNTH103 favorably, given its higher affinity and potency compared to riliprubart in multiple in vitro studies.
Furthermore, the sustained response rates and improvements in clinical outcomes such as grip strength and neurofilament light chain reductions add to the confidence in DNTH103’s potential. These factors, alongside the differentiation of active C1s inhibitors from other treatment classes like FcRn inhibitors, support the Buy rating. The financial metrics, including a manageable cash burn and a reasonable cash runway, further reinforce the positive outlook for Dianthus Therapeutics.
Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., VYNE Therapeutics, and Dianthus Therapeutics. According to TipRanks, Katkhuda has an average return of 13.3% and a 37.21% success rate on recommended stocks.
In another report released on May 13, Robert W. Baird also maintained a Buy rating on the stock with a $50.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue